EDAP Adds Capital Markets Veteran David Horn to Board Amid Growth Push

Event summary

  • David Horn joined EDAP’s board on February 11, 2026, bringing capital markets expertise and medical device industry experience.
  • Horn previously served as CFO of Seer, Inc. and held leadership roles at Morgan Stanley in healthcare investment banking.
  • He will serve on the Audit Committee and Nominations Committee, replacing Glen French who stepped down February 10, 2026.

The big picture

EDAP’s appointment of David Horn reflects a strategic pivot toward capital markets expertise as it seeks to scale its focal therapy technology. The move comes amid broader industry consolidation in medical devices, where financial agility is increasingly critical for expansion into new indications. With Horn’s background in healthcare investment banking and operational leadership, EDAP appears positioned to accelerate its growth trajectory beyond prostate cancer treatments.

What we're watching

Capital Markets Strategy
How Horn’s investment banking background will shape EDAP’s capital allocation and strategic transactions.
Board Composition Shift
Whether the addition of a finance-focused director signals near-term M&A or financing moves.
Growth Execution
The pace at which EDAP can expand clinical indications beyond prostate cancer under new board guidance.

Related topics

Medical Devices